Immunization of healthy adult subjects in the United States with inactivated Mycobacterium vaccae administered in a three-dose series

Clinical Infectious Diseases

Volumn 24, Issue 5, 1997, Pages 843-848

  Von Reyn, C F ^a   Arbeit, R D ^b   Yeaman, G ^b   Waddell, R D ^b   Marsh, B J ^b   Morin, Paul ^b   Modlin, John F ^b   Remold, Heinz G ^b  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARABINOMANNAN; ARABINOSE; BCG VACCINE; IMMUNOGLOBULIN G ANTIBODY; INACTIVATED VIRUS VACCINE; PHYTOHEMAGGLUTININ; TUBERCULIN;

ADULT; AGED; ANTIBODY TITER; ARTICLE; BCG VACCINATION; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG SAFETY; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMUNIZATION; IMMUNOGENICITY; INTRADERMAL DRUG ADMINISTRATION; LYMPHOCYTE PROLIFERATION; MALAISE; MALE; MYCOBACTERIUM AVIUM; MYCOBACTERIUM VACCAE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN TEST; UNITED STATES;

EID: 0030945189     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/24.5.843     Document Type: Article

References (27)

1. Engbaek HC, Jespersen A. Effect of BCG vaccination on experimental infection with M. avium. Acta Pathol Microbiol Scand 1966;67:503-13.
2. Collins FM. Protection to mice afforded by BCG vaccines against an aerogenic challenge by three mycobacteria of decreasing virulence. Tubercle 1985;66:267-76.
3. Orme IM, Collins FM. Prophylactic effect in mice of BCG vaccination against nontuberculous mycobacterial infections. Tubercle 1985;66:117-20.
4. Kallenius G, Hoffner SE, Svenson SB. Does vaccination with bacille Calmette-Guérin protect against AIDS? Rev Infect Dis 1989;11:349-51.
5. Katila ML, Brander E, Backman A. Neonatal BCG vaccination and mycobacterial cervical adenitis in childhood. Tubercle 1987;68:291-6.
6. von Reyn CF, Arbeit RD, Tosteson ANA, et al. The international epidemiology of disseminated Mycobacterium avium complex infection in AIDS. AIDS 1996;10:1025-32.
7. Horsburgh CR, Hanson DL, Jones JL, Thompson SE. Protection from Mycobacterium avium complex disease in human immunodificiency virus-infected persons with a history of tuberculosis. J Infect Dis 1996;174:1212-7.
8. von Reyn CF, Clements J, Mann JM. HIV infection and routine childhood immunization. Lancet 1987;2:669-72.
9. Weltman AC, Rose DN. The safety of bacille Calmette-Guerin vaccination in HIV infection and AIDS. AIDS 1993;7:149-57.
10. Stanford JL. Immunotherapy for leprosy and tuberculosis. Prog Drug Res 1989;33:415-48.
11. Stanford JL, Rook GA, Bahr GM, et al. Mycobacterium vaccae in immunoprophylaxis and immunotherapy of leprosy and tuberculosis. Vaccine 1990;8:525-30.
12. Stanford JL, Bahr GM, Rook GA, et al. Immunotherapy with Mycobacterium vaccae as an adjunct to chemotherapy in the treatment of pulmonary tuberculosis. Tubercle 1990;71:87-93.
13. Stanford JL, Bahr GM, Byass P, et al. A modern approach to the immunotherapy of tuberculosis. Bulletin of the International Union Against Tuberculosis 1990;65:27-9.
14. Stanford JL, Paul RC. A preliminary report on some studies of environmental mycobacteria from Uganda. Ann Soc Belg Med Trop 1973;53:389-93.
15. von Reyn CF, Magnusson M. Use and standardization of the Mycobacterium avium sensitin skin-test reagent. Clin Infect Dis 1995;21:1527-8.
16. Khoo K, Dell A, Morris H, Brennan PJ, Chatterjee D. Inositol phosphate capping of the nonreducing termini of lipoarabinomannin from rapidly growing strains of Mycobacterium. J Biol Chem 1995;276:12380-9.
17. Brewer MA, Edwards KM, Palmer PS, Hinson HP. Bacille Calmette-Guerin immunization in normal healthy adults. J Infect Dis 1994;170:476-9.
18. Hart PD. Efficacy and applicability of mass BCG vaccination in tuberculosis control. Br Med J 1967;1:587-92.
19. Comstock GW. Identification of an effective vaccine against tuberculosis. Am Rev Respir Dis 1988;138:479-80.
20. Fine PEM. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995;346:1339-45.
21. Palmer CE, Long MW. Effects of infection with atypical mycobacteria on BCG vaccination and tuberculosis. Am Rev Respir Dis 1966;94:553-68.
22. Bloom BR, Fine PE. The BCG experience: implications for future vaccines against tuberculosis. In: Bloom BR, ed. Tuberculosis: pathogenesis, protection, and control. Washington, DC: American Society for Microbiology, 1994:531-57.
23. von Reyn CF, Maslow JN, Barber TW, Falkinham JO, Arbeit RD. Persistent colonization of potable water as a source of Mycobacterium avium infection in patients with AIDS. Lancet 1994;343:1137-41.
24. Horsburgh CR. Epidemiology of disease caused by Mycobacterium avium complex. Canadian Journal of Infectious Diseases 1994;5(suppl B):5B-9B.
25. Chatterjee D, Lowell K, Rivoire B, McNeil MR, Brennan PJ. Lipoarabinomannin of Mycobacterium tuberculosis: capping with mannosyl residues in some strains. J Biol Chem 1992;267:6234-9.
26. von Reyn CF, Green PA, McCormick D, et al. Dual skin testing with Mycobacterium avium sensitin and purified protein derivative: an open study of patients with M. avium complex infection or tuberculosis. Clin Infect Dis 1994;19:15-20.
27. Menzies R, Vissandjee B, Rocher I, St. Germain Y. The booster effect in two step tuberculin testing among young adults in Montreal. Ann Intern Med 1994;120:190-8.